lenvatinib,sunitinib,everolimus,pembrolizumab
merck,pfizer,eisai
['sunitinib', 'clear trial', 'pembro']
final pre-specified 4-year os analysis of clear trial adjusted for subsequent anti cancer therapy demonstrates ongoing os benefit of len+pembro vs sunitinib with adjusted hr of 0.55. greatest benefit seen in intermediate/poor risk group. #asco23 
DAVA Oncology is a strategic consulting company that offers numerous products and services customized to fit biopharmaceutical drug development needs.